Clinical trials
Metastatic Solid Tumor clinical trials
Below are recruiting metastatic solid tumor clinical trials, each written for real people, not researchers. We’re tracking 1,103 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04794972RecruitingPhase 1
Testing a targeted antibody for advanced solid tumors
This Phase 1 trial tests a new antibody drug (GNC-039) that targets a specific feature found on some cancer cells. It is for adults with solid tumors that have come back or stopped responding to standard treatment, aiming to see safety and early signs of effectiveness.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07602842RecruitingPhase 1/Phase 2
Testing IDP-001 for advanced solid tumors
This early-stage trial tests a new drug called IDP-001 in people with advanced cancers that have spread or cannot be surgically removed. The study aims to find the right dose and see how well the drug works against various solid tumors.
Los Angeles, CaliforniaAges 18 years+ - NCT07403721RecruitingPhase 1
Study of AMG 436 for MSI-H/dMMR Cancers
This study tests an experimental drug called AMG 436, alone or with other treatments, for people with advanced solid tumors that have a specific genetic change (MSI-H or dMMR). The goal is to see if the drug can shrink tumors and if it is safe.
Irvine, CaliforniaAges 18–99 - NCT06619587RecruitingPhase 1
Study of GDC-7035 for advanced solid tumors with KRAS G12D
This trial tests a new oral drug (GDC-7035) for people with advanced solid tumors that have a specific KRAS mutation (G12D). The drug may be given alone or with other treatments to see if it is safe and helps fight the cancer.
La Jolla, CaliforniaAges 18 years+ - NCT07594626RecruitingPhase 1/Phase 2
BMS-986504 and Pemetrexed for Advanced Tumors With MTAP Loss
This trial tests a new drug (BMS-986504) combined with an existing chemotherapy (pemetrexed) for advanced solid cancers that have a specific genetic change called MTAP deletion. The trial aims to see if this combination can slow or stop tumor growth in patients whose cancer has progressed despite prior treatment.
Chicago, IllinoisAges 18 years+ - NCT07681882RecruitingPhase 1
Testing DS1025a in people with advanced solid tumors
This trial tests a new drug, DS1025a, for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it is safe and how well it works.
KashiwaAges 18 years+ - NCT07193511RecruitingPhase 1/Phase 2
A new drug for advanced bladder and other solid tumors
This trial tests a new drug, AVZO-103, alone or with other treatments, for people with advanced bladder cancer or certain other solid tumors. It aims to find out if the drug is safe and effective.
San Francisco, CaliforniaAges 18 years+ - NCT06803680RecruitingPhase 1
Study of BGB-B455 for advanced solid tumors
This trial tests a new drug, BGB-B455, for people with advanced solid tumors that have not responded to other treatments. It focuses on tumors that have a specific marker called CLDN6, especially in ovarian cancer.
Celebration, FloridaAges 18 years+ - NCT05687136RecruitingPhase 1
Study two targeted drugs for solid tumors with DNA repair changes
This Phase 1 trial tests how safe and effective two anti-cancer drugs (peposertib and tuvusertib) are for advanced solid tumors. It focuses on cancers with specific DNA repair and cell-growth gene changes, aiming to shrink tumors and improve outcomes when standard treatments have stopped working.
Bethesda, MarylandAges 18 years+ - NCT05269381RecruitingPhase 1/Phase 2
Personalized cancer vaccine with pembrolizumab for advanced solid tumors
This trial tests a personalized vaccine made from your tumor's unique markers, combined with the drug pembrolizumab, to help your immune system fight cancer. It is for people with advanced solid tumors who have already tried standard treatments.
Jacksonville, FloridaAges 16 years+ - NCT07623369RecruitingPhase 1
First-in-Human Study of HH160 for Advanced Solid Tumors
This is an early-stage trial testing a new drug called HH160 in patients with advanced cancer (solid tumors). Researchers want to find the right dose and learn how well it works and what side effects it causes.
Waratah, New South WalesAges 18–75 - NCT06172478RecruitingPhase 2
HER3-DXd for advanced solid tumors after prior treatment
This trial tests a new targeted drug called HER3-DXd for people with several types of advanced solid tumors that have stopped responding to standard treatments. The drug is an antibody-drug conjugate, designed to deliver chemotherapy directly to cancer cells that have a protein called HER3 on their surface.
Duarte, CaliforniaAges 18 years+ - NCT03454035RecruitingPhase 1
Combination of two study drugs for advanced pancreatic and other solid tumors
This trial tests two drugs, ulixertinib and palbociclib, taken together to see if they can shrink tumors in patients with advanced pancreatic cancer, melanoma, or other solid tumors. It may be an option for people who have already tried standard treatments.
Chapel Hill, North CarolinaAges 18–99 - NCT06120283RecruitingPhase 1
Testing a new drug for breast cancer and other solid tumors
This trial tests a new oral drug (BGB-43395) alone or with other treatments for people with advanced breast cancer or other solid tumors that depend on CDK4. It aims to find safe doses and see if the drug helps shrink tumors or slow growth.
Denver, ColoradoAges 18 years+ - NCT05733949RecruitingEarly Phase 1
Targeted radiation for people with many solid tumor metastases
This trial tests a precise type of radiation that targets multiple tumor spots in a carefully planned way. It may help people with many metastatic (spread) solid tumors when standard treatments aren’t working or can’t be used.
Duarte, CaliforniaAges 18 years+ - NCT06578624RecruitingPhase 1/Phase 2
SA53-OS for advanced solid tumors
This trial tests an experimental drug (SA53-OS) for people with advanced solid tumors or certain lymphomas whose tumors have a normal p53 gene. The goal is to see if it is safe and helps shrink or slow the cancer.
Canton, OhioAges 18 years+ - NCT06799065RecruitingPhase 1
Testing a new drug for advanced solid tumors
This trial tests ATX-295, a daily pill that blocks a protein called KIF18A, in people with advanced solid tumors, including ovarian cancer. It is for those whose cancer has grown after standard treatments or who cannot have standard therapy.
Aurora, ColoradoAges 18 years+ - NCT05461768RecruitingPhase 1
BL-M07D1 for HER2-positive or HER2-low breast cancer
This Phase 1 study tests BL-M07D1, a new investigational medicine, in people with HER2-positive or HER2-low breast cancer (and other solid tumors) that can’t be operated on or has spread. It aims to find a safe dose and learn how well the treatment may work based on HER2 levels in tumor tissue.
Fuzhou, FujianAges 18–75 - NCT07231211RecruitingPhase 1/Phase 2
Testing SHR-4610 for advanced solid tumors
This trial tests a new drug called SHR-4610 for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective, and may be an option if you have a measurable tumor and are generally in good health.
Hangzhou, ZhejiangAges 18–75 - NCT07196644RecruitingPhase 2
A study of a new drug for certain cancers with a specific gene change
This trial tests a drug called telisotuzumab adizutecan for people whose cancer has a specific genetic change called MET amplification. It may help when standard treatments are no longer working.
Beverly Hills, CaliforniaAges 12 years+ - NCT07335497RecruitingPhase 1/Phase 2
Experimental drug CR-001 for advanced solid tumors
This trial tests an experimental drug called CR-001 in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if CR-001 can slow or stop tumor growth.
Birmingham, AlabamaAges 18 years+ - NCT07416123RecruitingPhase 1
Study of a new drug for advanced solid tumors
This trial tests an experimental drug, GEN1106, for people with solid tumors that have not responded to standard treatments. It aims to see if the drug can help shrink or control the cancer.
New Haven, ConnecticutAges 18 years+ - NCT06797336RecruitingPhase 1
Study of PT0253 for advanced KRAS G12D mutated tumors
This trial tests an experimental drug called PT0253 for people with advanced or metastatic cancers that have a specific genetic change called KRAS G12D. The drug may help shrink or slow the growth of these tumors, and the study will also check for side effects.
Los Angeles, CaliforniaAges 18 years+ - NCT05875168RecruitingPhase 1/Phase 2
Study of DS-3939a for Advanced Solid Tumors
This trial is testing a new drug called DS-3939a for people with advanced solid tumors that have not responded to other treatments. The study has two parts to find the right dose and see how well it works.
Sarasota, FloridaAges 18 years+
Hear when a new Metastatic Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Metastatic Solid Tumor trials by city
Studies with a site in or near these metro areas.
Metastatic Solid Tumor trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for metastatic solid tumor?
- Yes. Clin2 currently lists 1,103 recruiting metastatic solid tumor studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a metastatic solid tumor trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a metastatic solid tumor trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.